BackAvadel Pharmaceuticals plc Overview

Avadel Pharmaceuticals plc Operating Income

Latest operating income for AVDL: $4.5M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$1.94M
692.35% YoY

As of Sep 30, 2025

Annual Operating Income (TTM)

$4.52M
107.07% YoY

Trailing 12 months ending Sep 30, 2025

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Avadel Pharmaceuticals plc (AVDL) FAQ

Avadel Pharmaceuticals plc (AVDL) currently reports a operating income of $4.5M as of September 2025. That compares with $-64M in the prior-year period — up 107.1% year over year. Use the charts on this page to explore Avadel Pharmaceuticals plc's operating income history and peer comparisons.

Avadel Pharmaceuticals plc's operating income increased from $-64M to $4.5M — a 107.1% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avadel Pharmaceuticals plc reported $4.5M in operating income as of September 2025. That compares with $-64M in the prior-year period — up 107.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $4.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Avadel Pharmaceuticals plc, and consider following AVDL for alerts when major investors trade the stock.

Avadel Pharmaceuticals plc is classified in the Healthcare sector. On operating income, it currently shows $4.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVDL with unrelated industries.